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Background/Objectives:  
The Mesothelioma and Radical Surgery 2 (MARS 2) trial was established in the UK to evaluate the role 
of radical surgery, (Pleurectomy decortication), for the treatment of malignant pleural mesothelioma 
(MPM). It compares chemotherapy and surgery to chemotherapy alone. The feasibility trial included a 
nested qualitative sub-study. The sub study aimed to 1) understand the patient experience of MARS2 
trial process and interventions and 2) Identify any information and support needs required by patients. 
We present here the results related to MARS2 pDUWLFLSDQW¶V information experiences and needs at the 
point of randomisation. Implications for information provision to enhance patient experience and 
overcome recruitment barriers1 within MPM trials are considered.  
Methods: 41 in-depth longitudinal qualitative methods were used with 15 participants following 
randomisation. 9 participants received chemotherapy and surgery and 6 received chemotherapy alone. 
Interviews were conducted following randomisation, and at 6 and 12 months after the initial interviews. 
Participants randomised to surgery also had an interview after post-operative discharge. Data was 
collected between August 2015 and March 2017 and analysed using Framework analysis2. 
Results  
The findings provide insight into the challenging context within which potential participants have to 
assimilate knowledge about a trial such as MARS2. Prior to hearing about the trial participants had 
encountered a diverse range of new and concerning experiences. These included worrying symptoms, 
diagnostic tests, investigations and the drainage of litres of fluid from the lung. They had to absorb an 
array of life-changing facts in a short time including that they had a rare incurable cancer with a poor 
prognosis; their illness was an occupational disease with legal and financial implications due to 
asbestos exposure. Participants attended their trial consultation soon after this challenging diagnostic 
information provision. The study reveals variations in understanding of the trial procedures, specifically 
decision-making regarding treatments, equipoise and the process of randomisation. Motivations for 
participating in the trial were identified along with preferences for information formats. 
Conclusion  
This study provides unique insight into the information pathway of MPM trail participants, from diagnosis 
to randomisation. Results suggest that improvements in presentation of trial information and the 
development of formats that can be tailored to individual needs and preferred ways of learning, many 
enhance experience of and recruitment to MPM trials. Working with patients to co-produce information 
that communicates challenging concepts effectively, (such as randomisation and equipoise), may be a 
useful approach to meeting this challenge. 
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